bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Inclusion Criteria: * Cutaneous warts on ingers and/or palms and/or toes and/or soles of feet * Common warts and mosaic warts, diagnosed by an experienced dermatologist * Solitary wart lesions or 2 or more lesions per patient * Lesions present for more than 6 months * Men or women, aged 18 or above * History of kidney transplantation and immune suppressive therapy after transplant * Concomitant immune suppressive therapy stable for 6 months prior to randomization * Agreement from patient to allow photographs to be taken and used as part of trial data documentation (2 centres) * Women of childbearing potential must have negative pregnancy test at screening and must use adequate contraception * Ability to comply with requirements of trial * Written informed consent Exclusion Criteria: * Verruca plana lesions * Suspected allergy to milk verified by serum analysis of IgE towards cow milk * Breastfeeding * Any local medication for any purpose other than wart treatment in target area during 4 weeks prior to randomization and during treatment period * Concomitant treatment with other wart therapies two weeks prior to randomization and during trial period * Intolerance towards bovine alpha-lactalbumin, oleic acid or any excipient in the formulation * Known HIV infection or any current uncontrolled infection * Any chronic or acute skin condition susceptible of interfering with evaluation of drug effect in this trial * Participation in any investigational trial or use of any investigational drug within 30 days prior to inclusion in this trial * Any health problems which according to Investigator's clinical judgment will make the patient unsuitable for inclusion in the trial